Evidence map›Paper›PMID 40500109›Full record

ArticleJournal for immunotherapy of cancer2025

IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma.

Wenyi Yang, Zhaoyang Guo, Houyu Ju, Yusheng Lu, Yifan Fei, Yuanchen Yin, Guoxin Ren, Ming Yan, Chaofeng Han, Jingzhou Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Chemoradiotherapy facilitates siglec-10Cancer immunology, immunotherapy : CII · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenyi Yang *Department of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.ORCID http://orcid.org/0000-0002-6038-8233
Zhaoyang Guo *Department of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Houyu Ju *Department of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Yusheng LuDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.ORCID http://orcid.org/0009-0001-2542-4323
Yifan FeiDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Yuanchen YinDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.ORCID http://orcid.org/0000-0001-8944-2785
Guoxin RenDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Ming YanDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China.
Chaofeng HanDepartment of Histology and Embryology, National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China huyayi@shsmu.edu.cn hcf@immunol.org.
Jingzhou HuDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai, China huyayi@shsmu.edu.cn hcf@immunol.org.ORCID http://orcid.org/0000-0003-4402-3370

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint blockade therapy has shown limited efficacy in head and neck squamous cell carcinoma (HNSCC). Sialic acid binding immunoglobulin-like lectin (Siglec)-15 has been identified as a novel immune evasion biomarker, while the role of Siglec-10 in the specific immune suppressive tumor microenvironment remains largely unknown.

methodsImmunohistochemical assays were employed to investigate the correlation of the expressions of Siglec-10 and Siglec-15 with the clinicopathological features as well as the prognosis of immunotherapy in patients with HNSCC. The Gene Expression Omnibus datasets were used to identify the upstream transcriptional regulators of

resultsThe expression of Siglec-G/10, rather than that of Siglec-15, was positively correlated with immune suppressive marker programmed death-ligand 1 (PD-L1) expression and was associated with cervical lymph node metastasis, poorer pathologic stage, and lower sensitivity to immunotherapy.

conclusionsOur results suggest that high Siglec-G/10 expression aggravates the immune suppressive tumor microenvironment and impedes the immunotherapy efficacy in HNSCC, which indicates that targeting Siglec-G/10 may represent a promising therapeutic option for improving the immunotherapy efficacy in HNSCC.

Indexed as

Head and Neck NeoplasmsImmunotherapyInterleukin-4LectinsSquamous Cell Carcinoma of Head and NeckSTAT6 Transcription FactorTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMaleMiceMiddle AgedInterleukin-4LectinsSTAT6 protein, humanSTAT6 Transcription FactorHead and Neck CancerImmune Checkpoint InhibitorImmunotherapyJAK-STATMacrophage

Identifiers

PMID40500109
PMCPMC12161403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.